Biotech Values

[RockRat]

CTMX: Tech does look interesting. Here's an article - in which the methodology looks pretty solid to my undertrained eye - about their technique (free registration required; the nerdier among us probably already have AAS access):

Tumor-Specific Activation of an EGFR-Targeting Probody Enhances Therapeutic Index

But one wonders where the competition is. Why couldn't other players could try this approach based on the upregulated stuff in the tumor microenvironment? Have you looked at that? So far, the only one that looks close to me is Igenica (private), but I've only just started looking. Their S-1 makes no mention of Igenica, it seems a closer competitor than any others listed. Seattle Genetics appears to be investigating the role of tumor associate macrophages in processing ADCs, but both they and Igenica are still preclinical - at best - with this stuff, as far as I know.

FWIW, I sold a small batch of puts on CTMX recently, and it looks as though I'll be there proud owner of a small batch of shares next week.

Regards, RockRat